Linked Life Data

10933182

Source:http://linkedlifedata.com/resource/pubmed/id/10933182

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2000-12-12
pubmed:abstractText
Multiple myeloma is still an incurable disease. The standard conventional chemotherapy comprises melphalan and prednisone (MP). Combination chemotherapy regimens could not improve the median survival of 36 months observed with MP. In the French IFM90 study, HD therapy with TBI plus melphalan 140 mg/m2 was shown to prolong overall survival and progression-free survival compared to conventional treatment. Nonetheless, most patients eventually succumb due to disease progression. Allogeneic transplantation may induce long-term remissions and even cure, but is hampered by a high transplantation-related mortality (TRM). Currently, efforts are made to reduce this TRM and to evaluate the graft-versus-myeloma effect.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
25 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S25-6
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Autologous and allogeneic stem cell transplantation in multiple myeloma.
pubmed:affiliation
Medizinische Klinik und Poliklinik V, Universität Heidelberg, Germany.
pubmed:publicationType
Journal Article, Review